𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Management of punding in Parkinson’s disease: an open-label prospective study

✍ Scribed by A. Fasano; L. Ricciardi; M. Pettorruso; A. R. Bentivoglio

Book ID
106095121
Publisher
Springer
Year
2010
Tongue
English
Weight
141 KB
Volume
258
Category
Article
ISSN
0340-5354

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

CQP 201-403 in Parkinson's disease: An o
CQP 201-403 in Parkinson's disease: An open-label pilot study
✍ Dr. Ronald F. Pfeiffer; Leonel H. Herrera; Carolyn S. Glaeske; Ruth E. Hofman 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 249 KB 👁 1 views

The dopamine agonist, CQP 201-403, was administered to 10 patients in an open label fashion with rapid dosage escalation during hospitalization. Assessed over a n average of 20 days, significant improvement occurred in bradykinesia, rigidity, and postural instability. Tremor did not occur in suffici

An open-label conversion study of pramip
An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease
✍ Kelly E. Lyons; Rajesh Pahwa 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB

## Abstract Ropinirole prolonged release (PR) is a once daily oral dopamine agonist approved for the treatment of Parkinson's disease (PD). The goal of this 4 week, open‐label study was to determine the most effective conversion ratio with the fewest adverse effects (AEs) when switching from pramip

Caffeine in Parkinson's disease: A pilot
Caffeine in Parkinson's disease: A pilot open-label, dose-escalation study
✍ Robert D. Altman; Anthony E. Lang; Ronald B. Postuma 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 314 KB 👁 1 views

## Abstract ## Introduction: Epidemiologic studies consistently find an inverse association between caffeine use and PD. Numerous explanations exist, but are difficult to evaluate as caffeine's symptomatic effect and tolerability in PD are unknown. ## Patients and Methods: We designed an open‐la